FFA
BBIO icon

Farther Finance Advisors’s BridgeBio Pharma BBIO Stock Holding History

Farther Finance Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.8K Sell
1,243
-230
-16% -$16.1K ﹤0.01% 2770
2026
Q1 		$110K Buy
1,473
+960
+187% +$69.6K ﹤0.01% 2446
2025
Q4 		$39.2K Buy
513
+245
+91% +$16.1K ﹤0.01% 2976
2025
Q3 		$13.9K Buy
268
+58
+28% +$2.83K ﹤0.01% 3260
2025
Q2 		$9.07K Sell
210
-14
-6% -$509 ﹤0.01% 3122
2025
Q1 		$7.4K Buy
224
+24
+12% +$809 ﹤0.01% 2877
2024
Q4 		$5.49K Buy
200
+63
+46% +$1.63K ﹤0.01% 2628
2024
Q3 		$3.47K Buy
137
+41
+43% +$1.08K ﹤0.01% 2795
2024
Q2 		$2.42K Buy
96
+5
+5% +$137 ﹤0.01% 2715
2024
Q1 		$2.73K Sell
91
-5
-5% -$170 ﹤0.01% 2360
2023
Q4 		$3.88K Buy
96
+91
+1,820% +$2.73K ﹤0.01% 2098
2023
Q3 		$132 Buy
+5
New +$142 ﹤0.01% 2525

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Farther Finance Advisors's BBIO Position: Q2 2026 in Review

Farther Finance Advisors reduced its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, selling an estimated $16.1K and leaving 1,243 shares worth $91.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Farther Finance Advisors first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $110K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Farther Finance Advisors held 1,243 shares of BridgeBio Pharma worth $91.8K as of Q2 2026.
  • Farther Finance Advisors sold 230 BridgeBio Pharma shares in Q2 2026, an estimated $16.1K.
  • BridgeBio Pharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #2770 holding.
  • Farther Finance Advisors first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's BridgeBio Pharma position peaked at $110K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.